Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

Distribution expansion

10 Mar 2009 07:00

RNS Number : 5744O
LiDCO Group Plc
10 March 2009
 



Press Release 

10th March 2009

LiDCO Group Plc

("LiDCO" or the "Company")

Distribution Expansion in Germany

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce further expansion of its distribution network. The Company has signed a distribution agreement for the sale of its LiDCOrapid Monitor and disposables in Germany with Absolute Medical GmbH & Co. KG based in RatingenGermany. With LiDCO's existing north German distribution partner, the agreement gives LiDCO access to the biggest hemodynamic monitoring market in Europe.

With a population of 82 million people, Germany ranks as the third largest medical device market in the world (behind the USA and Japan) and represents 36% by value of the European medical device marketAt around 10.6% of GDP, healthcare expenditure in Germany is currently at a high level creating a demand for sophisticated medical equipment which has demonstrated significant improvements in clinical outcome.

Absolute Medical was recently founded by Bradley Gould an experienced CEO with 28 years of experience in the global medical device industry. Absolute Medical's focus is on sales and distribution of advanced medical devices in Germany to hospital acute care, critical care and anaesthesia departments. 

Absolute Medical's CEO Mr Bradley Gould commented "We are very excited to have the opportunity to introduce this new technology to the largest European hemodynamic monitoring market. We have great belief in LiDCO's products and are confident that with our deep knowledge of the hemodynamic monitoring market in Germany, we expect to have great success marketing the LiDCOrapid.

Dr Terry O'Brien, CEO LiDCO Group plc, commented:  "We are delighted to have further broadened our distribution, which means we now have sales reach to the majority of EuropeThe LiDCOrapid is an innovative solution that provides a cost effective, highly accurate solution for monitoring high-risk surgical patients. Working with two distribution partners in Germany means that LiDCO now has full access to the biggest medical device market in Europe."

- ENDS - 

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com 

Panmure Gordon and Co

Edward Farmer/ Katherine Roe

+44 (0)20 7459 3600

www.panmure.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves

+44 (0)20 7398 7728

simone.alves@abchurch-group.com 

www.abchurch-group.com 

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care has been shown to:

- Contribute to reduced morbidity and complications

- Reduce length of stay

- Reduce overall cost of care

* LiDCO single patient use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

* LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors

LiDCO Distribution Network:

The Company sells direct in the UK, direct and elsewhere through a worldwide network of speciality critical care and anesthesia distributors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGGFNLNGLZM
Date   Source Headline
1st May 20147:00 amRNSPositive haemodynamic monitoring study
29th Apr 20147:00 amRNSFinal Results
7th Apr 20147:00 amRNSNotice of Results and Investor briefing
17th Mar 20147:00 amRNSLaunch of New Version of LiDCOrapid software
12th Mar 20147:00 amRNSResults of cost effectiveness trial
28th Feb 201411:34 amRNSTotal Voting Rights
12th Feb 20147:00 amRNSTrading update and notice of results
7th Feb 20149:21 amRNSHolding(s) in Company
28th Jan 20143:01 pmRNSHolding(s) in Company
27th Jan 20144:10 pmRNSBlocklisting Application
20th Jan 20149:54 amRNSReplacement:Anaesthetists guidelines supports LID
20th Jan 20147:00 amRNSAnaesthetists guidelines supports LiDCO
18th Oct 20134:04 pmRNSExercise of Share Options
1st Oct 20137:00 amRNSHalf Yearly Report
26th Sep 20137:00 amRNSNotice of Patent Acceptance
20th Sep 20137:00 amRNSInvestor Results Briefing
6th Sep 20134:33 pmRNSHolding(s) in Company
4th Sep 20137:00 amRNSFDA clearance
20th Aug 20137:00 amRNSTrading update
13th Aug 201312:11 pmRNSNotification of major interest in shares
12th Jun 201311:43 amRNSResults of Annual General Meeting
12th Jun 20137:00 amRNSAGM Statement
10th Jun 201310:08 amRNSNotification of major interest in shares
5th Jun 20137:00 amRNSLiDCOrapid in successful recovery programme
31st May 20139:50 amRNSGrant of Share Options
17th May 20133:30 pmRNSNotice of AGM and posting of Annual Report
9th May 20137:00 amRNSLiDCOrapidv2 incorporated in NHS Foundation Trust
8th May 20133:51 pmRNSExercise of Share Options
23rd Apr 20137:00 amRNSPreliminary Results
26th Mar 20137:00 amRNSUS FDA clears for sale LiDCOrapidv2
15th Mar 20137:00 amRNSGrant of LiDCOrapid user interface patent in Japan
22nd Feb 20133:25 pmRNSDirector/PDMR Shareholding
21st Feb 201312:45 pmRNSExercise of Share Options
7th Feb 20137:03 amRNSLaunch and first sales of the LiDCOrapid v2
5th Feb 20137:00 amRNSTrading Update and Notice of Preliminary Results
17th Dec 20127:00 amRNSTrading Statement
29th Nov 20122:00 pmRNSTR-1 Notification of Major Interest in Shares
27th Nov 20127:00 amRNSExercise of Share Options
27th Nov 20127:00 amRNSProtocol using LiDCOrapid improves outcomes
23rd Nov 20127:00 amRNSLiDCOrapid v2 satisfies NICE recommendation
13th Nov 20127:00 amRNSFundraising to raise £2.35 million
23rd Oct 20127:00 amRNSInterim Results
15th Oct 20123:00 pmRNSExercise of Share Options
15th Oct 20127:00 amRNSPremier of LiDCOrapid v2 with Unity Software
14th Sep 20123:20 pmRNSNotice of Interim Results
3rd Sep 201212:00 pmRNSExercise of Share Options
23rd Aug 20127:00 amRNSTrading update and resignation of Director
3rd Aug 20127:00 amRNSNihon Kohden appointed as distributor in Japan
11th Jul 20127:00 amRNSReimbursement approval received in Japan
4th Jul 20123:05 pmRNSGrant of Share Option

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.